The role of [18F]FDG PET/CT in paraneoplastic autoimmune disorders: an umbrella review.
Détails
ID Serval
serval:BIB_4307E0AEBAAC
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
The role of [18F]FDG PET/CT in paraneoplastic autoimmune disorders: an umbrella review.
Périodique
The quarterly journal of nuclear medicine and molecular imaging
ISSN
1827-1936 (Electronic)
ISSN-L
1824-4785
Statut éditorial
Publié
Date de publication
09/2022
Peer-reviewed
Oui
Volume
66
Numéro
3
Pages
229-233
Langue
anglais
Notes
Publication types: Journal Article ; Meta-Analysis
Publication Status: ppublish
Publication Status: ppublish
Résumé
Paraneoplastic autoimmune disorders (PAD) are a group of autoimmune diseases associated with neoplasms. Several evidence-based articles (systematic reviews and meta-analyses) have reported data about the role of positron emission tomography (PET) and related hybrid modalities (e.g., PET/CT) using 2-deoxy-2-[18F]fluoro-D-glucose ([ <sup>18</sup> F]FDG) in patients with PAD. We performed an umbrella review of published systematic reviews and meta-analyses in this setting to provide an evidence-based summary and suggestions for further studies. Several databases were searched to find systematic reviews and meta-analysis on [ <sup>18</sup> F]FDG PET/CT in PAD. Evidence-based data support the use of [ <sup>18</sup> F]FDG PET/CT in patients with suspected PAD for investigating an underlying malignancy even if it is still unclear whether [ <sup>18</sup> F]FDG PET/CT should be performed after negative/inconclusive conventional imaging or as part of the initial workup of PAD.
Mots-clé
Autoimmune Diseases/diagnostic imaging, Fluorodeoxyglucose F18, Humans, Neoplasms, Positron Emission Tomography Computed Tomography, Positron-Emission Tomography/methods
Pubmed
Création de la notice
31/05/2022 9:47
Dernière modification de la notice
14/06/2023 5:56